Clinical Trials
37 trialsStudy to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
BAF_FRontier-1
Eli Lilly and Company
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger, Inc.
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences, Inc.
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
MAPLE-1
Ascentage Pharma Group Inc.
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings, Inc.
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Xencor, Inc.
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
X4 Pharmaceuticals
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Hutchmed
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
AbbVie
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
TG Therapeutics, Inc.
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
ADC Therapeutics S.A.
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Celgene
Study of MLN8237 in Participants With Advanced Hematological Malignancies
Takeda
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Calithera Biosciences, Inc
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Janssen Research & Development, LLC
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Amgen
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Zenith Epigenetics
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Millennium Pharmaceuticals, Inc.
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Millennium Pharmaceuticals, Inc.
PCYC-04753
Pharmacyclics LLC.
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
Vertex Pharmaceuticals Incorporated
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
MedImmune LLC